Testing a video app on HIV treatment and transmission for people with HIV
Tests a video app on HIV treatment in adults living with HIV in South Africa.
Key facts
- Who runs it
- Boston University
- Where
- Johannesburg, South AfricaSee the site
- Trial code
- Registry title
- Integrating U=U Into HIV Counseling in South Africa (INTUIT-2.0)
- Status
- Recruiting
- People taking part
- 880 people, planned
- Started
- 5 Oct 2026
- Expected to end
- Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- "Undetectable & You" HIV treatment literacy app
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who just had HIV post-test or adherence counselling at a taking-part public clinic in South Africa. It tests a video app that explains U=U.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- People must have had HIV post-test counselling or adherence counselling.
Main reasons for not taking part
- Needs urgent medical care that the study would get in the way of
- Clinic staff judge the person not physically or emotionally able to start ART
- Cannot consent, for example because of intoxication or limited mental capacity
- Does not speak English, Zulu, Sotho or Tsonga
- Prisoners or other institutionalized persons
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Clinic inclusion criteria:
- Public sector facility
- Primary care, outpatient clinic
- Follows national guidelines for HIV counseling
- Has dedicated HIV counselors
- At least 10 patients receiving HIV counseling per week (based on pre-study data)
- Follows national guidelines for lab monitoring (CD4 at diagnosis; VLs at 3 and 10 months on ART)
- Is interested in participating, as indicated by "sign-off" from the head nurse / facility director; Individual participant inclusion criteria:
- Adult (at least 18 years)
- Received HIV post-test counselling or adherence counseling
- Able to consent
- Provides informed consent
- Speaks one of the primary study languages: English, Zulu, Sotho, Tsonga
- Receives care at the facility as evidence by having a clinical record there; Individual participant exclusion Criteria:
- Require acute medical care that would be hindered by participation in the study
- Determined by clinical staff not to be physically or emotionally able to initiate ART
- Children (under 18 years)
- Prisoners or other institutionalized persons
- Do not speak one of the primary study languages: English, Zulu, Sotho
- Are not able to consent (e.g. intoxicated or of limited mental capacity)
- Do not consent to participate in the study, including linkage to clinical records for follow-up
This trial is currently available in South Africa.
- University of WitwatersrandJohannesburg, South AfricaContact: Dorina Onoya, PhD MBATaking people
About the trial
What the trial wants to find out
Undetectable = Untransmittable (U=U) is the scientific consensus that people with human immunodeficiency virus (HIV) who achieve viral suppression through antiretroviral treatment (ART) cannot transmit the virus sexually. While global studies confirm this, awareness of U=U remains very limited in sub-Saharan Africa, including South Africa, where only two-thirds of people living with HIV (PLHIV) are virally suppressed despite having the largest treatment program globally. Many PLHIV delay or avoid ART because they feel healthy and perceive little benefit, while also fearing stigma, disclosure, and social costs. U=U offers powerful motivation for ART uptake and adherence by reframing treatment as both a personal health and prevention tool, reducing internalised stigma, strengthening self-image, and supporting HIV prevention altruism. Yet, dissemination in Africa has lagged. To address this, the investigators developed an HIV treatment literacy App called "Undetectable \& You", which delivers accurate U=U information alongside real-life video testimonials of PLHIV and their partners. This research will assess the impact of the "Undetectable \& You" App in a cluster-randomized trial in South Africa. The study will establish whether disseminating U=U information via a video-based app at the time of HIV counselling improves retention in care and viral suppression among PLHIV in South Africa.
Read full original descriptionShow less
Aim 1. Refine the "Undetectable \& You" App to help PLHIV navigate U=U within relationships.
Aim 2. Establish the real-world impact of "Undetectable \& You" on retention on ART and viral suppression in a cluster-randomized trial.
The 2 groups in the trial
- Immediate intervention Group ATreatment being tested
Participants whose clinic was randomized into Group A will have immediate access to the "Undetectable \& You" intervention app as part of HIV counseling.
Treatment: "Undetectable & You" HIV treatment literacy app
- Deferred intervention Group BExisting treatment, for comparison
Participants whose clinic was randomized into Group B will get the intervention app at 16 months, after data collection for primary outcomes is complete.
Treatment: "Undetectable & You" HIV treatment literacy app
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Integrating U=U Into HIV Counseling in South Africa (INTUIT-2.0): a Cluster-Randomized Trial
- Plain-language title
- Testing a video app on HIV treatment and transmission for people with HIVGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 November 2026